Is Tirzepatide legal in Tennessee?
status · caveats apply
FDA-approved GIP/GLP-1 dual agonist (Mounjaro/Zepbound); compounded copies broadly restricted post-shortage; FDA has issued 30+ Warning Letters to GLP-1 telehealth vendors. Tennessee AG led 38-state coalition letter to FDA (Feb 20, 2025) on counterfeit GLP-1s; Nashville compounding pharmacy was shut down after state inspection.
category: fda approved · last verified May 13, 2026
§ 01
Quick answer
FDA-approved GIP/GLP-1 dual agonist (Mounjaro/Zepbound); compounded copies broadly restricted post-shortage; FDA has issued 30+ Warning Letters to GLP-1 telehealth vendors. Tennessee AG led 38-state coalition letter to FDA (Feb 20, 2025) on counterfeit GLP-1s; Nashville compounding pharmacy was shut down after state inspection.
§ 02
Full status breakdown
Federal status
FDA approval
approved as drug · brand: Mounjaro, Zepbound · NDA 215866 (Mounjaro); NDA 217806 (Zepbound) · approved May 13, 2022
Indications: T2DM; chronic weight management; OSA
DEA scheduling
not scheduled
503A compounding
Bulks list: not on list
Do-not-compound list: not on list
Approved drug; 503A 'essentially a copy' rule applies post-shortage. 503A enforcement discretion ended Feb 18, 2025; 503B Mar 19, 2025. FDA proposed April 2026 to exclude tirzepatide from 503B bulks list.
FDA Warning Letters
- Dec 10, 2024 — Summit Research Peptides (cited: tirzepatide, retatrutide) · letter ↗
- Sep 9, 2025 — Hims & Hers Health Inc dba Hers (cited: tirzepatide, semaglutide) · letter ↗
- Feb 20, 2026 — Better Health Labs Inc dba Measured (cited: tirzepatide) · letter ↗
- Mar 31, 2026 — Gram Peptides (cited: tirzepatide, retatrutide) · letter ↗
Shortage status
Sale framing
Research-use-only posture: RUO label does not legalize sale to consumers when site evidence shows human-use intent. FDA has issued 30+ warning letters across 2024-2026.
Personal possession: Federally unscheduled; possession by an end-user is not a federal criminal offense, but unapproved compounded/illicit tirzepatide carries FDA enforcement risk on the seller side plus state pharmacy law risk.
Tennessee — state-specific
ag enforcement · Tennessee
Tennessee AG led 38-state coalition letter to FDA (Feb 20, 2025) on counterfeit GLP-1s; Nashville compounding pharmacy was shut down after state inspection.
- TN AG press release 2025-02-20 · verified May 13, 2026
Sport-body status
WADA 2026
on prohibited list · class S2 · both
S2 (Peptide hormones / GLP-1 agonist class). WADA does not name tirzepatide explicitly; class-language capture.
USADA
banned
NCAA
banned
What we couldn’t verify
§ 03
Also known as
Tirzepatide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
LY3298176MounjaroZepboundGIP/GLP-1 dual agonistTirzTirze
§ 04
Disclaimer
§ 05
Related
- Back to peptide legality lookup — pick a different compound or state
- Tirzepatide research guide — mechanism, dosing math, vendor audits, COA data
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch